Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P08908 (5-HT1A)
 5,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serotonin exerts an influence on the prenatal development of rat brain. However, later developmental times may be more applicable to the understanding of the role of serotonin in human developmental disorders. Therefore, the current study was undertaken to gain preliminary information on the postnatal effects of serotonin on rat brain development. As the 5-HT1A receptor has been shown to be involved in much of the developmental functions of serotonin, an agonist for this receptor, 8-hydroxy-DPAT (8-OH-DPAT), was used. Neonatal rat pups at three ages (postnatal days, PNDs) 3-10, 10-17 or 17-24) were injected daily with 1 mg/kg 8-OH-DPAT and evaluated for behavioral consequences. The youngest group showed accelerated incisor eruption and eye-opening, a possible consequence of 5-HT1A receptor interactions with epidermal growth factor (EGF). Behaviorally, the animals were more anxious. Animals treated from PND 10-17, showed no change in craniofacial development but showed greater behavioral maturity in measures of spontaneous alternation and activity in the open field. The oldest animals (PND 17-24) showed no behavioral alterations, suggesting that this time length is beyond the critical period for serotonin's influence in brain development.
 ...
PMID:Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. 922 68

N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) is a highly selective neurotoxin for noradrenergic projections originating from the locus coeruleus (LC). The outcome of the systemic DSP-4 treatment of newborn rats is an alteration in postnatal development of the noradrenergic system, involving the permanent denervation of distal noradrenergic projection areas (neocortex, hippocampus, spinal cord), accompanied by noradrenergic hyperinnervation in regions proximal to the LC cell bodies (cerebellum, pons-medulla). DSP-4 is well tolerated by developing rats and does not increase the mortality rate. Permanent noradrenergic denervation in the cerebral cortex and spinal cord is present at all developmental stages, although this effect is more pronounced in rats treated with DSP-4 at an early age, i.e., up to postnatal day 5 (PND 5). Notably, regional hyperinnervation is a hallmark of neonatal DSP-4 treatment, which is not observed after either prenatal or adult DSP-4 application. In contrast to robust biochemical changes in the brain, DSP-4 treatment of newborn rats has a marginal effect on arousal and cognition functions assessed in adulthood, and these processes are critically influenced by the action of the noradrenergic neurotransmitter, norepinephrine (NE). Conversely, neonatal DSP-4 does not significantly affect 5-hydroxytryptamine (serotonin; 5-HT), dopamine (DA), gamma-aminobutyric acid (GABA), and histamine levels in brain. However, as a consequence of altering the functional efficacy of 5-HT1A, 5-HT1B, DA, and GABA receptors, these neurotransmitter systems are profoundly affected in adulthood. Thus, the noradrenergic lesion obtained with neonatal DSP-4 treatment represents a unique neurobiological technique for exploring the interplay between various neuronal phenotypes and examining the pathomechanism of neurodevelopmental disorders.
...
PMID:Selective Lifelong Destruction of Brain Monoaminergic Nerves Through Perinatal DSP-4 Treatment. 2642 51